Should I buy Parkway Life stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Parkway Life for over three years. Every month, hundreds of thousands of users in Singapore trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Parkway Life.

What is Parkway Life?

How much is Parkway Life stock?

The price of Parkway Life stock is stable this week. Parkway Life is currently trading at SGD 4.11, with a slight 24-hour decrease of SGD 0.01, unchanged over the past week. The REIT’s market cap stands at SGD 2.68 billion and it sees an average daily volume of 1.01 million units. Parkway Life has a P/E ratio of 26.5, a dividend yield of 3.63%, and a low beta of 0.28. Investors benefit from the stability and defensive nature of healthcare real estate, making this stock attractive for long-term portfolios in Singapore.

Our full analysis of Parkway Life stock

Having thoroughly reviewed Parkway Life’s recent financial results and its performance over the past three years, we have synthesised key insights from financial indicators, technical signals, market dynamics, and peer benchmarks using proprietary algorithms. This comprehensive analysis provides a robust perspective on Parkway Life’s position in the REIT-healthcare space. So, why might Parkway Life stock once again become a strategic entry point into the healthcare and real estate sector in 2025?

Recent performance and market context

Parkway Life currently trades at SGD 4.11, reflecting remarkable stability amidst wider market volatility. Over the last week, its price has remained flat, following a notable 8.73% gain in the past six months and an impressive 15.77% increase over one year. These figures underline strong resilience and consistent demand for defensive yield assets in Singapore.

On the fundamental side, Parkway Life maintains its position as a market leader through prudent capital management and a focus on resilient income streams, despite minor revenue pressure from Yen depreciation in 2024. Offsetting this, the REIT completed landmark acquisitions—including 11 care homes in France—strengthening its geographic and income diversification. The healthcare REIT sector, supported by demographic trends and robust government spending in APAC, continues to offer an attractive macroeconomic backdrop for steady growth and reliable returns.

Technical analysis

Technical signals reinforce Parkway Life’s current attractiveness. The RSI sits at a neutral 54.13, indicating balanced supply and demand without signs of overheating or downward momentum. The MACD barely positive at 0.01 suggests a subtle buy signal, while stochastic oscillators confirm a stable trading environment.

Crucially, Parkway Life’s price hovers above strong support at SGD 3.98—providing reassurance for buyers—and remains close to both the 20- and 50-day moving averages, which are themselves trending upward. The 200-day moving average has acted as a dynamic support throughout the year, creating a technical floor near SGD 3.95. Should the stock break above resistance at SGD 4.23, further upside could follow as new capital is drawn by technical confirmation. The convergence of these indicators highlights solid short- and medium-term momentum, highly unusual—and attractive—in a rate-sensitive REIT sector.

Fundamental analysis

From a fundamental perspective, Parkway Life stands out for its income reliability and growth visibility:

• Revenue and profitability: FY 2024 revenue reached SGD 145.3 million, exhibiting only marginal decline year-on-year despite currency headwinds, while distributable income rose by 2.3% to SGD 91.4 million. Distributions per unit continue to set new highs with a current yield of 3.63%.
• Valuation strength: The current P/E ratio of 26.5 is justified by Parkway Life’s unique portfolio, sector leadership, and strong support from institutional investors. Its market cap of SGD 2.68 billion, combined with a prudent gearing of 34.8%, offers reassurance on both liquidity and solvency.
• Structural moat: Parkway Life boasts the largest portfolio of private hospitals in Singapore, “sticky” long-term master leases (averaging 20.4 years), and a growing base of healthcare and aged care assets across Singapore, Japan, and now France.
• Brand and ESG: An unwavering focus on healthcare excellence and ESG credentials enhances both tenant retention and investor confidence, which is increasingly valued by global capital.

Consistent performance through economic cycles, combined with acquisitive expansion and inflation-linked rental structures (over two-thirds of income indexed to CPI), positions Parkway Life at the intersection of growth and defensiveness in the SG context.

Volume and liquidity

Sustained trading volumes—averaging 1.01 million units daily—signal deep market confidence and ample liquidity for institutional and retail participants alike. This robust float, underpinned by a well-governed REIT structure, enables ease of entry and exit, supporting dynamic valuation adjustment as new information emerges.

The stability of Parkway Life’s traded volume, even during market corrections, points to a committed investor base. This deep liquidity ensures the stock remains tradable without excessive price swings, further highlighting its attractiveness compared to less liquid REIT peers.

Catalysts and positive outlook

Several powerful catalysts make the Parkway Life investment case particularly compelling:

• International diversification: The recent entry into France with the acquisition of 11 care homes not only enhances income resilience but also unlocks future growth in continental Europe, broadening the REIT’s geographic footprint beyond a traditionally Singapore- and Japan-centric portfolio.
• Defensive sector positioning: Healthcare real estate is uniquely insensitive to economic downturns, benefiting from secular demographics (aging population in APAC and Europe) and committed public/private health spending.
• Inflation-protected growth: Approximately 67% of rental income is explicitly indexed to inflation (CPI-linked), offering rare protection in an uncertain global rate environment.
• Strong capital management: The successful SGD 180 million equity raising in November 2024 highlights market appetite for the Parkway Life growth story; ample capital resources underpin ongoing expansion and yield sustainability.
• Favourable regulatory context: Singapore’s stable and transparent REIT regulatory regime, paired with robust investor safeguards, creates a highly supportive environment for public market growth.
• Leadership and governance: Highly experienced management, led by CEO Yong Yean Chau, ensures strategy execution and risk discipline, while external management by Parkway Trust Management provides both scale and sector expertise.

These clear and actionable catalysts appear timed to further accelerate Parkway Life’s established growth trajectory, supporting both yield stability and asset appreciation.

Investment strategies

For investors considering Parkway Life, the current window offers distinct opportunities across varied horizons:

• Short-term traders may look to exploit near-term technical support at SGD 3.98, which has proven resilient, and consider entry ahead of potential resistance breakout at SGD 4.23.
• Medium-term investors can capitalise on the strong yield visibility and upside from newly acquired European assets. The progressive roll-out of portfolio enhancements and realisation of cross-border synergies could induce upward revisions to analyst estimates.
• Long-term holders benefit from Parkway Life’s unique business model, sector leadership, strong ESG focus, and unmatched stability within the REIT sector—all set against an inexorable trend of demographic ageing.
• Tactical positioning ahead of major announcement windows (distribution declarations, acquisition closures, or regulatory changes) also offers prudent investors the chance to maximise returns from both income spikes and capital appreciation.

Historically, entry points at or near technical supports or prior to known growth catalysts have yielded outsized rewards for patient investors.

Is it the right time to buy Parkway Life?

In summary, Parkway Life seems to represent an excellent opportunity for both income-focused and growth-oriented investors in the Singapore market. Its consistent dividend performance, prudent capital structure, and ability to deliver year-after-year growth even when faced with external headwinds establish a solid investment foundation. Geographic diversification, inflation protection, and sector leadership create a fundamentally strong and attractive profile that stands out within both the local and regional REIT landscape.

With analysts indicating a further 15% potential upside and robust market sentiment, Parkway Life appears poised to enter a new bullish phase. Its blend of resilience and growth, coupled with supportive technicals and healthy trading liquidity, justify renewed interest from those seeking a defensive yet rewarding real estate play.

For investors in Singapore, Parkway Life offers a rare balance of low volatility, stable yield, and exciting forward-looking catalysts—a combination that increasingly points to this REIT as a desirable cornerstone in any modern, robust portfolio.

How to buy Parkway Life stock in Singapore?

Buying Parkway Life stock online is safe, quick, and straightforward when using a regulated broker in Singapore. Investors have two main options: buying shares directly (spot buying) or trading via Contracts for Difference (CFDs), each with benefits depending on your investment goals and risk profile. Make sure to check out the broker comparison further down the page for the most suitable choice for your needs.

Spot buying

A cash purchase of Parkway Life stock means you actually own the shares, which are held in your brokerage account on the Singapore Exchange (SGX). Most local brokers charge a fixed commission per trade, typically around SGD 5–10.

Gain scenario

If the Parkway Life share price is SGD 4.11, you can buy around 242 shares with a SGD 1,000 stake, including a brokerage fee of about SGD 5.

If the share price rises by 10%, your shares are now worth SGD 1,100. Result: +SGD 100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Parkway Life shares lets you speculate on the price without owning the shares. This approach involves fees such as the spread (the difference between buy and sell prices) and possibly overnight financing charges if you hold positions for more than a day.

Gain scenario

You open a CFD position on Parkway Life shares, with 5x leverage and a SGD 1,000 stake. This gives you a market exposure of SGD 5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +SGD 400 gain, on a bet of SGD 1,000 (excluding fees).

Final advice

Always compare broker fees and trading conditions before investing—see our broker comparison below for guidance. The best method depends on your aims: spot buying suits long-term investors seeking ownership, while CFDs may appeal to active traders looking for leverage and flexibility.

Our 7 tips for buying Parkway Life stock

The latest news about Parkway Life

Parkway Life shares maintain strong support from Singapore investors amid sector resilience. The REIT remains one of the most stable and defensive plays on the SGX, supported by long-term leases for its prime private hospitals (Mount Elizabeth, Gleneagles, Parkway East) in Singapore. This local portfolio anchors recurring income and attracts steady institutional and retail inflows.

Recent financial results highlight distributable income growth and sustained dividend increases. For FY2024, Parkway Life reported a 2.3% increase in distributable income, allowing for a higher distribution per unit of 14.92 cents. This trend reflects management’s ability to offset minor revenue declines—linked to JPY fluctuations—by acquiring additional healthcare assets, ultimately ensuring reliable income for Singapore investors.

The REIT’s solid technical indicators signal renewed investor confidence in the Singapore market. Trading above all key moving averages and with a MACD buy signal, Parkway Life’s share price is currently driven by optimism regarding defensive healthcare real estate and its attractive yield. The consensus target price of SGD 4.74 implies further upside, reinforcing its reputation as a safe haven in volatile markets.

Strategic acquisitions and portfolio diversification support outlook for growth and stability. Parkway Life made notable moves in 2024, entering the European market with French nursing home assets and further expanding its Japanese footprint. These moves diversify geographic risk and demonstrate active capital management, which are both highly valued by Singaporean investors seeking balance between yield and growth.

Long-term fundamentals remain positive with inflation protection and strong demographic tailwinds. With 67.2% of rental income indexed to CPI and a sector driven by regional population ageing, Parkway Life is well cushioned against inflation and cyclical shocks. Its dominant local footprint and focus on healthcare future-proof the REIT as a core SGX holding for income-oriented investors.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.